Table 2. IgG1/IgG2a antibody production against MCMV and myosin is affected by type I IFN treatment.
| Anti-MCMV antibody | Anti-myosin antibody | |||
|---|---|---|---|---|
| IFN subtype* | IgG1 | IgG2a | IgG1 | IgG2a |
| Vehicle | 6·8 ± 0·1 | 2·0 ± 0·0 | 4·0 ± 0·0 | 2·2 ± 0·1 |
| pkCMVint.IFNα1 | 6·8 ± 0·2 | 2·0 ± 0·0 | 3·8 ± 0·2 | 2·4 ± 0·2 |
| pkCMVint.IFNα2 | 6·2 ± 0·2 | 2·0 ± 0·0 | 3·4 ± 0·2 | 2·2 ± 0·2 |
| pkCMVint.IFNα4 | 7·0 ± 0·0 | 2·0 ± 0·0 | 3·8 ± 0·2 | 2·2 ± 0·2 |
| pkCMVint.IFNα5 | 6·0 ± 0·0† | 2·0 ± 0·0 | 3·8 ± 0·2 | 2·4 ± 0·2 |
| pkCMVint.IFNα6 | 5·6 ± 0·2‡ | 2·0 ± 0·0 | 3·0 ± 0·4 | 2·0 ± 0·0 |
| pkCMVint.IFNα9 | 7·0 ± 0·0 | 7·0 ± 0·0‡ | 4·6 ± 0·2 | 2·0 ± 0·0 |
| pkCMVint.IFNβ | 5·8 ± 0·2‡ | 2·0 ± 0·0 | 2·8 ± 0·2‡ | 2·0 ± 0·0 |
*
DNA (200 μg) was injected bilaterally into regenerating TA muscles of adult mice 5 days after bupivacaine treatment. Fourteen days following DNA injections mice were challenged with 1 × 104 PFU MCMV i.p. and sera were harvested at day 7. Data are presented as log2 serum antibody titre ± SEM for IgG1 and IgG2a.
†
P ≤ 0·05.
‡
P ≤ 0·01.